Diligence memo · auto-generated · as of July 2, 2026
Lygos, Inc.
Lygos, Inc. has raised $42M over 4 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Lygos, Inc. operates in Biotech, based in BERKELEY, CA, USA. Lygos engineers yeast to convert sugar into high-value industrial…
Sub-sector tags: Biotechnology, Climate, Synthetic Biology, biotech, climate/cleantech.
Capital & rounds (filed)filed
Lygos, Inc. has raised $42M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $16M on 2018-03-13.
Most recent recorded round closed around 2018-11-09.
Valuation (modeled)modeled
Provath models Lygos, Inc. at approximately $433M (range $22M–$1.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 7.6 yr ago; this sector typically re-raises about every 11 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 97% of Biotech peers (233 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: Arix Bioscience plc, Yield10 Bioscience, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.